Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 6:46 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1753–1776 of 4,220 matching trials from the live ClinicalTrials.gov search.
Completed Phase 4 Interventional Results available

The Montefiore Metoclopramide Study

NCT00475306
Conditions
Nausea, Extrapyramidal Symptoms
Interventions
metoclopramide 10 mg, Diphenhydramine 25 mg, Placebo, Metoclopramide 20 mg
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
21 Years to 65 Years
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
The Bronx, New York
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates

NCT07703514
Conditions
Influenza
Interventions
cH15/3, cH4/3, cH5/1N1, cH8/1N1, Saline
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 59 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Active, not recruiting Phase 2 Interventional Results available

RANKL Inhibition and Mammographic Breast Density

NCT04067726
Conditions
Dense Breasts
Interventions
Denosumab, Placebo, Calcium, Vitamin D3, Core needle biopsy, Blood draw
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
40 Years and older · Female only
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
COPD
Interventions
OnabotulinumtoxinA, Placebo
Drug · Other
Lead sponsor
RMW Testing
Industry
Eligibility
18 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Webster, Texas
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of TAK-105 in Healthy Adults

NCT04964258
Conditions
Healthy Volunteers
Interventions
TAK-105-a, TAK-105-a Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
3
States / cities
Tempe, Arizona • Las Vegas, Nevada • Austin, Texas
Conditions
Osteoarthritis Knee Pain
Interventions
SL1002, Normal Saline
Drug
Lead sponsor
Saol Therapeutics Inc
Industry
Eligibility
40 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
22
States / cities
Roseville, California • San Diego, California • Greenwood Village, Colorado + 19 more
Completed Phase 2 Interventional Results available

A Study of CT-868 in Type 1 Diabetes Mellitus

NCT06062069
Conditions
Overweight, Obese, Type 1 Diabetes Mellitus
Interventions
CT-868, CT-868 Pen Injector, CT-868 Pen Injector, Placebo
Drug · Device
Lead sponsor
Carmot Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
22
States / cities
Concord, California • Escondido, California • Aurora, Colorado + 17 more
Conditions
Seasonal Allergic Rhinitis
Interventions
Placebo (0.5ml), Placebo (1.0ml), Grass MATA MPL (0.5ml) 5100SU, Grass MATA MPL (1.0ml) 10200SU, Grass MATA MPL (1.0ml) 18200SU, Grass MATA (0.5ml) 5100SU
Biological
Lead sponsor
Allergy Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Neptune City, New Jersey
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Study in Participants With Acute Migraines Headaches

NCT00804973
Conditions
Migraine Headache
Interventions
LY2590443, Placebo injection, Sumatriptan, Placebo capsule
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
19
States / cities
Beverly Hills, California • Chula Vista, California • Fresno, California + 16 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dopaminergic Modulation of Brain Activation Using Simultaneous PET/Pharmacological MRI

NCT03326245
Conditions
Normal Physiology
Interventions
Methylphenidate Pill, Oral Placebo, Intravenous Placebo, Intravenous methylphenidate
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Healthy Adult
Interventions
DTI-117, Placebo
Drug
Lead sponsor
Dignify Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Austin, Texas
Not listed Not applicable Interventional Accepts healthy volunteers

Medicinal vs. Orthotic Comparison for Migraine Prevention: A Double-Blind Study

NCT04547179
Conditions
Migraine
Interventions
Fremanezumab-Vfrm, BLAfit®, Saline
Drug · Device · Other
Lead sponsor
Manhattan Beach Orthodontics
Other
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Manhattan Beach, California
Conditions
Type 1 Diabetes
Interventions
liraglutide, placebo
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 75 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
2
States / cities
Buffalo, New York
Conditions
Alcohol Use Disorder, Alcoholism
Interventions
XR-NTX 380 mg, intramuscular injection, Medical Management, Placebo intramuscular injection
Drug · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Platysma Prominence
Interventions
NT 201, NT 201 Placebo
Drug
Lead sponsor
Merz Aesthetics GmbH
Industry
Eligibility
18 Years to 65 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Aventura, Florida • Coral Gables, Florida + 3 more
Conditions
Plaque Psoriasis
Interventions
Secukinumab, Ustekinumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
123
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 103 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations

NCT04761822
Conditions
SARS-CoV Infection, COVID-19, Allergic Reaction, Mast Cell Disorder
Interventions
Moderna COVID-19 Vaccine, Pfizer-BioNTech COVID-19 Vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
5 Years and older
Enrollment
746 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
29
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 24 more
Conditions
Head and Neck Cancer
Interventions
PepCan, Placebo
Biological
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 100 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Little Rock, Arkansas
Terminated Phase 1Phase 2 Interventional Results available

Study of ExoFlo for the Treatment of Perianal Fistulas

NCT05836883
Conditions
Perianal Fistula, Crohn's Disease
Interventions
ExoFlo, Local injection of normal saline
Biological · Other
Lead sponsor
Direct Biologics, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Recruiting Phase 1 Interventional Accepts healthy volunteers

First Time in Human Study of Long Acting VH4524184 Formulations

NCT06310551
Conditions
HIV Infections
Interventions
Oral VH4524184, VH4524184 Formulation A SC, Placebo Formulation A SC, rHuPH20, VH4524184 Formulation B SC, Placebo Formulation B SC, VH4524184 Formulation A IM, Placebo Formulation A IM, VH4524184 Formulation B IM, Placebo Formulation B IM
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
372 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
3
States / cities
Lenexa, Kansas • San Antonio, Texas • Salt Lake City, Utah
Conditions
Myocardial Infarction, Myocardial Ischemia
Interventions
thymosin beta 4, Placebo
Drug · Other
Lead sponsor
RegeneRx Biopharmaceuticals, Inc.
Industry
Eligibility
18 Years to 79 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2017
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Depressive Disorder, Major
Interventions
Rapastinel, Placebo
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 65 Years
Enrollment
429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
40
States / cities
Dothan, Alabama • Phoenix, Arizona • Imperial, California + 34 more
Conditions
Atopic Dermatitis
Interventions
Tezepelumab, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
16
States / cities
Fountain Valley, California • Santa Monica, California • Alpharetta, Georgia + 12 more
Conditions
Chronic Cluster Headache
Interventions
Galcanezumab 300 mg, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
14
States / cities
Phoenix, Arizona • Santa Monica, California • Stanford, California + 10 more